Last reviewed · How we verify
N-acetylcysteine 500 mg
At a glance
| Generic name | N-acetylcysteine 500 mg |
|---|---|
| Also known as | Mucolítico, Sanitas, Chile |
| Sponsor | Pontificia Universidad Catolica de Chile |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Effects of NAC on Symptoms of CHR Patients (NA)
- Individualized Multiplex Pathophysiological Treatment of Severe Acute Infections: N-Acetylcysteine (PHASE4)
- Imaging Acetadote Metabolism in Glioblastoma (EARLY_PHASE1)
- Evaluation of the Role of N Acetyl Cysteine and Vitamin D in Improving Outcomes After Corrosive Ingestion (PHASE3)
- N-Acetyl Cysteine Effect on Liver Function After Mitral Valve Replacement (PHASE4)
- A Trial of 2 Disease-Modifying Drugs (Metformin and N-acetylcysteine ) to Promote TB Lung Function Recovery (PHASE3)
- FDOPA PET and Nutritional Support in Parkinson's Disease (PHASE2)
- PET-MRI in Chronic Traumatic Brain Injury (CTBI) (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- N-acetylcysteine 500 mg CI brief — competitive landscape report
- N-acetylcysteine 500 mg updates RSS · CI watch RSS
- Pontificia Universidad Catolica de Chile portfolio CI